Sinalização JAK/STAT
Os inibidores da sinalização JAK/STAT são compostos que interrompem a via da Janus quinase (JAK) e do transdutor e ativador da transcrição (STAT), que está envolvida na sinalização de citocinas, crescimento celular e resposta imunológica. Esses inibidores são ferramentas importantes para estudar a regulação dessa via e seu papel em diversas doenças, incluindo cânceres, distúrbios imunológicos e condições inflamatórias. Os inibidores de JAK/STAT também estão sendo desenvolvidos como terapias direcionadas para essas doenças. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de sinalização JAK/STAT de alta qualidade para apoiar sua pesquisa em biologia molecular, oncologia e imunologia.
Subcategorias de "Sinalização JAK/STAT"
Foram encontrados 321 produtos de "Sinalização JAK/STAT"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Ilginatinib hydrochloride
CAS:<p>Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H21ClFN7Pureza:99.55%Cor e Forma:SolidPeso molecular:425.89N-(3-Aminopropyl)cyclohexylamine
CAS:<p>N-(3-Aminopropyl)cyclohexylamine inhibits spermine synthase; used in neuro disease research.</p>Fórmula:C9H20N2Pureza:98.05% - 98.82%Cor e Forma:Pale Yellow Clear LiquidPeso molecular:156.2685Pim-1 kinase inhibitor 8
CAS:<p>Pim-1 kinase inhibitor 8 is a Pim-1 kinase inhibitor with anticancer activity that inhibits cell migration and can be studied in breast cancer.</p>Fórmula:C14H17N3O3Pureza:99.81%Cor e Forma:SoildPeso molecular:275.3TAK-901
CAS:<p>TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others</p>Fórmula:C28H32N4O3SPureza:99.02% - 99.59%Cor e Forma:SolidPeso molecular:504.64KT-333
CAS:<p>KT-333 is a potent, highly selective, heterobifunctional degrader of STAT3 for the treatment of a variety of STAT3-dependent pathologies, antitumor.</p>Fórmula:C60H74ClN10O14PSPureza:98.12%Cor e Forma:SolidPeso molecular:1257.78Gusacitinib
CAS:<p>Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).</p>Fórmula:C24H28N8O2Pureza:98.06% - 99.94%Cor e Forma:SolidPeso molecular:460.53Delgocitinib
CAS:<p>Delgocitinib is a potent JAK inhibitor (IC50: 2.8-58 nM), treats inflammatory diseases, and is the first topical drug for atopic dermatitis.</p>Fórmula:C16H18N6OPureza:99.95%Cor e Forma:SolidPeso molecular:310.35Ilginatinib
CAS:<p>Ilginatinib (NS-018) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C21H20FN7Pureza:98.4% - 99.01%Cor e Forma:SolidPeso molecular:389.43Ilginatinib maleate
CAS:<p>Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable inhibitor of JAK2.</p>Fórmula:C25H24FN7O4Pureza:99.74% - 99.82%Cor e Forma:SolidPeso molecular:505.5Golidocitinib
CAS:<p>Golidocitinib (AZD4205) is a selective JAK1 inhibitor (IC50: 73 nM) and weakly inhibits JAK2/JAK3 (IC50: >14.7, >30 μM).</p>Fórmula:C25H31N9O2Pureza:98.87% - 99.88%Cor e Forma:SolidPeso molecular:489.57Bromisoval
CAS:<p>Bromisoval (Isobromyl) is a mild hypnotic and sedative with potential toxicity.</p>Fórmula:C6H11BrN2O2Pureza:98.86%Cor e Forma:SolidPeso molecular:223.07Nimucitinib
CAS:<p>Nimucitinib is a Janus kinase (JAK) inhibitor that can be used to treat dry eye and promote tear production.</p>Fórmula:C25H26F2N6O2Pureza:98.71%Cor e Forma:SoildPeso molecular:480.51Brepocitinib P-Tosylate
CAS:<p>Brepocitinib P-Tosylate (PF-06700841 P-Tosylate) is a potent dual inhibitor of Janus kinase 1 (JAK1) and TYK2 (IC50s of 17 nM and 23 nM, respectively).</p>Fórmula:C25H29F2N7O4SPureza:99.82% - 99.97%Cor e Forma:SolidPeso molecular:561.6JAK2 Inhibitor V
CAS:<p>JAK2 Inhibitor V (JAK2 Inhibitor V Z3) is a novel specific inhibitor of Jak2, inhibiting Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner.</p>Fórmula:C23H24N2OPureza:98.36% - 99.15%Cor e Forma:SolidPeso molecular:344.45WDR5-IN-6
CAS:<p>WDR5-IN-6 is a WDR5 inhibitor targeting the WBM locus.WDR5-IN-6 is highly synergistic with OICR-9429, a WDR5 inhibitor that targets the WIN locus.WDR5-IN-6</p>Fórmula:C13H8Cl2N2O2SPureza:99.69%Cor e Forma:SoildPeso molecular:327.19Uzansertib phosphate
CAS:<p>Uzansertib phosphate (INCB053914 phosphate) is an orally active, ATP-competitive inhibitor of pan-PIM kinase, inhibiting PIM1, PIM2 and PIM3.</p>Fórmula:C26H29F3N5O7PPureza:99.75% - 99.79%Cor e Forma:SolidPeso molecular:611.51STAT4-IN-1
<p>STAT4-IN-1 is a STAT4 inhibitor with a Ki of 0.35 μM. It holds promise for research into autoimmune diseases, including inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, and diabetes.</p>Cor e Forma:Odour SolidPM-81I
CAS:<p>PM-81I: Potent STAT6 inhibitor for allergic and pulmonary conditions, cancer research. Reduces STAT6 phosphorylation.</p>Fórmula:C43H58F2N3O10PCor e Forma:SolidPeso molecular:845.91Pim-1 kinase inhibitor 11
<p>Pim-1 kinase inhibitor 11 (10f) is an inhibitor of PIM-1 with an IC50 value of 0.18 μM. It exhibits anticancer activity by inducing apoptosis and causing cell cycle arrest.</p>Cor e Forma:Odour SolidJAK-IN-15
CAS:<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Fórmula:C22H23FN4O3SCor e Forma:SolidPeso molecular:442.51JAK-2/3-IN-1
CAS:<p>JAK-2/3-IN-1 inhibits JAK-2/3 isoforms with sub-250 nM Ki; from US patent US8163732B2.</p>Fórmula:C20H12ClN3OCor e Forma:SolidPeso molecular:345.79Eflepedocokin alfa
CAS:<p>Eflepedocokin alfa is a recombinant IL-22/IgG2-Fc protein, potentially protecting cells and enhancing immune function and tissue repair.</p>Cor e Forma:LiquidAS2553627
CAS:<p>AS2553627 is a JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts.</p>Fórmula:C18H19N5OCor e Forma:SolidPeso molecular:321.38JAK1/TYK2-IN-1
CAS:<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Fórmula:C18H20F3N7OCor e Forma:SolidPeso molecular:407.401AK-2292
<p>AK-2292: potent STAT5 PROTAC degrader, DC50 0.10 μM, degrades STAT5A/B, may shrink leukemia tumors in mice.</p>Fórmula:C52H54F2N7O10PS2Cor e Forma:SolidPeso molecular:1070.13CMD178
<p>CMD178 is an important polypeptide that consistently reduces the expression of Foxp3 and STAT5 by inhibiting the IL-2/s IL-2Rα signaling pathway.</p>Fórmula:C46H59N9O7Pureza:98%Cor e Forma:SolidPeso molecular:850.03SJ10542
CAS:<p>SJ10542: potent JAK2/3-targeting PG-PROTAC; DC50s: JAK2 - 14 nM, JAK3 - 11 nM, JAK2-fusion ALL - 24 nM; CRBN recruiter.</p>Fórmula:C41H46N12O5SCor e Forma:SolidPeso molecular:818.95JAK2-IN-10
CAS:<p>JAK2-IN-10 (compound 5) is a potent inhibitor of JAK2v617f, with an IC50 value of ≤10 nM.</p>Fórmula:C33H33D3FN9O2Cor e Forma:SolidPeso molecular:612.71SJ1008030 formic
<p>SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an</p>Fórmula:C43H45N13O9SPureza:98%Cor e Forma:SolidPeso molecular:919.96Axltide
CAS:<p>Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.</p>Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9)
CAS:<p>Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide derived from mouse JAK2, specifically composed of amino acids 475 to 491.</p>Fórmula:C88H138N20O34P2Pureza:98%Cor e Forma:SolidPeso molecular:2082.1JAK-IN-29
<p>JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].</p>Fórmula:C17H14ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:355.78JI069
CAS:<p>JI069 (WAY-354189) is a potent STAT3 inhibitor that inhibits gp130 signaling by inducing dissociation between gp130 and JAK1.</p>Fórmula:C15H12Cl2N2O4SPureza:98.01%Cor e Forma:SolidPeso molecular:387.24JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67Pumecitinib
CAS:<p>Pumecitinib is a Janus kinase (JAK) inhibitor. Pumecitinib exhibits anti-inflammatory activity.</p>Fórmula:C17H20N8O2SPureza:99.94%Cor e Forma:SoildPeso molecular:400.46LH168
<p>LH168 is a potent and selective probe for WDR5, with a SPR Kd value of 13 nM.</p>Fórmula:C29H31F3N6O2SCor e Forma:SolidPeso molecular:584.66JAK2-IN-6
CAS:<p>JAK2-IN-6: A potent JAK2-specific inhibitor (IC50=22.86μg/mL), blocks JAK2 signaling, has anticancer properties, and is inactive against JAK1/3.</p>Fórmula:C14H10ClN3OS2Pureza:99.64%Cor e Forma:SolidPeso molecular:335.83STAT3 degrader-1
CAS:<p>STAT3 Degrader-1 (Compound 295) is a potent degrader of STAT3, utilized in anticancer research [1].</p>Fórmula:C58H63F5N9O12PSCor e Forma:SolidPeso molecular:1236.2JAK-STAT Compound Library
<p>A unique collection of 252 JAK/STAT signaling targeted compounds for high throughput and high content screening;</p>Cor e Forma:Odour SolidSTAT5-IN-3
<p>STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer properties. It works by blocking the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites, significantly reducing the expression of the STAT5B protein. This leads to the inhibition of downstream gene transcription, thereby preventing the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 has significant potential in overcoming chemotherapy resistance.</p>Fórmula:C25H27N5OCor e Forma:SolidPeso molecular:413.51JAK3-IN-15
<p>JAK3-IN-15 (compound 22) is a JAK3 inhibitor that reduces the secretion of p-JAK3 induced by LPS. It is utilized in research for rheumatoid arthritis.</p>Cor e Forma:Odour SolidTYD-68
<p>TYD-68 is a potent and selective CRBN-recruiting TYK2 PROTAC degrader, with a DC50 value of 0.42 nM. This compound effectively inhibits IL-12 and IFN-α-induced phosphorylation of STAT4 and STAT1, thereby blocking TYK2-dependent signaling pathways. TYD-68 is applicable in psoriasis research.</p>Cor e Forma:Odour SolidR8-T198wt
CAS:<p>Cell-permeable peptide blocking Pim-1 kinase, halts DU145 cell growth, causes G1 arrest and apoptosis, inert to RPWE-1 cells at 10-20 μM.</p>Fórmula:C111H211N59O26SPureza:98%Cor e Forma:SolidPeso molecular:2820.33Tyk2-IN-22
CAS:<p>Tyk2-IN-22 (Compound A8) is a selective inhibitor of tyrosine kinase 2 (Tyk2), effectively inhibiting Tyk2, JAK1, and JAK3 with IC50 values of 9.7 nM, 148.6 nM, and 883.3 nM, respectively. Additionally, Tyk2-IN-22 suppresses downstream STAT5 phosphorylation.</p>Fórmula:C16H16ClN5O2Cor e Forma:SolidPeso molecular:345.78OSM-SMI-10B
<p>OSM-SMI-10B, a variant of OSM-SMI-10, inhibits OSM-induced STAT3 activation in cancer cells.</p>Fórmula:C21H14O7Cor e Forma:SolidPeso molecular:378.33JAK-IN-33
<p>JAK-IN-33 (Compound 3 (R)) is a selective inhibitor of the Janus kinase (JAK) family [1].</p>Pureza:98%Cor e Forma:Odour SolidSJ1008030
CAS:<p>SJ1008030, a JAK2 PROTAC, degrades JAK2; EC50: 5.4 nM, IC50: 32.09 nM in MHH-CALL-4 cells for leukemia research.</p>Fórmula:C42H43N13O7SCor e Forma:SolidPeso molecular:873.94APTSTAT3-9R
<p>APTSTAT3-9R-9R blocks STAT3 (Ki: 231 nmol/L), hindering cancer cell growth and resistance.</p>Fórmula:C223H330N80O51Pureza:98%Cor e Forma:SolidPeso molecular:4947.51FDA-Approved Kinase Inhibitor Library
<p>A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.</p>Cor e Forma:LiquidVB1080
<p>VB1080 (compound 12) is a potent PIM inhibitor with IC50 values of 69.5 µM for PIM1, 4996 µM for PIM2, and 9.88 µM for PIM3. Additionally, VB1080 exhibits cytotoxic properties and possesses anthelmintic activity.</p>Fórmula:C27H27N3O3Cor e Forma:SolidPeso molecular:441.522Neocucurbitacin A
CAS:<p>Neocucurbitacin A (compound 7), a STAT3 inhibitor extracted from the pericarp of Aquilaria crassna, serves as a potential agent for anticancer research [1].</p>Fórmula:C31H42O8Pureza:98%Cor e Forma:SolidPeso molecular:542.66SJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74JAK/HDAC-IN-4
<p>JAK/HDAC-IN-4 (compound 11 i) is a dual inhibitor targeting both JAK2 and HDAC6, with IC50 values of 0.49 nM and 12 nM respectively. It inhibits cell proliferation and the production of nitric oxide. In a mouse model induced by Imiquimod, JAK/HDAC-IN-4 ameliorates psoriasiform skin lesions with low toxicity.</p>Fórmula:C30H32N8O5SCor e Forma:SolidPeso molecular:616.69S-Ruxolitinib
CAS:<p>S-Ruxolitinib can be used in related research in the field of life sciences. Its product number is T3066 and CAS number is 1160597-27-2.</p>Fórmula:C17H18N6Pureza:98%Cor e Forma:SolidPeso molecular:306.37PROTAC TYK2 degradation agent1
CAS:<p>PROTAC TYK2 Agent1 selectively degrades TYK2, with a 14 nM DC50, for autoimmune research.</p>Fórmula:C55H69N13O7SPureza:98%Cor e Forma:SolidPeso molecular:1056.28TP-5801 TFA
<p>TP-5801 TFA is an orally active inhibitor of TNK1, a non-receptor tyrosine kinase, with an IC50 value of 1.40 nM, demonstrating anti-tumor activity [1].</p>Fórmula:C26H32BrF3N8O3Pureza:98%Cor e Forma:SolidPeso molecular:641.48Deuruxolitinib
CAS:<p>Deuruxolitinib functions as an inhibitor of JAK1/2.</p>Fórmula:C17H18N6Cor e Forma:SolidPeso molecular:314.41HAT-SIL-TG-1&AT
<p>HAT-SIL-TG-1&AT: a hypoxia-activated JAK inhibitor that curbs HEL cell growth & STAT3/5 phosphorylation in tumors.</p>Fórmula:C60H69N17O11SCor e Forma:SolidPeso molecular:1236.36MR44397
<p>MR44397 is a ligand for WD40 repeat (WDR) 5 and is applicable in cancer research.</p>Fórmula:C23H26N4O2SCor e Forma:SolidPeso molecular:422.54KT-333 diammonium
CAS:<p>KT-333 diammonium functions as a molecular glue that targets and degrades the STAT3 protein. It selectively mediates the degradation of STAT3 via the ubiquitin-proteasome pathway by attaching to STAT3 and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). This compound exhibits strong specificity in degrading STAT3 and demonstrates significant antitumor activity. KT-333 diammonium is applicable in researching hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).</p>Fórmula:C60H80ClN12O14PSCor e Forma:SolidPeso molecular:1291.84KT-333 ammonium
CAS:<p>KT-333 ammonium (Compound A) acts as a molecular glue that targets and promotes the degradation of the STAT3 protein through the ubiquitin-proteasome system. This compound achieves selective degradation by binding simultaneously to the STAT3 protein and the E3 ubiquitin ligase von Hippel-Lindau protein (VHL). It exhibits strong selectivity and efficacy in degrading STAT3, possessing notable antitumor properties. KT-333 ammonium is particularly useful for research on hematologic malignancies, including large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) [1].</p>Fórmula:C60H77ClN11O14PSCor e Forma:SolidPeso molecular:1274.81TYK2 activator-1
<p>TYK2activator-1 (16b) is a TYK2 activator with an EC50 value of 1.78 μM. It inhibits JAK2 and JAK3 with IC50 values of 6.8 μM and 6.3 μM, respectively.</p>Fórmula:C23H21FN4O2Cor e Forma:SolidPeso molecular:404.16485Fulipiftide
CAS:<p>Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). It stimulates the amplification of nuclear stem cell factor+TSPC by activating the ERK2 and STAT3 signaling pathways. Fulipiftide also exhibits anti-inflammatory properties and is applicable in research on acute tendon injuries.</p>Fórmula:C144H227N41O47Cor e Forma:SolidPeso molecular:3284.59DBL-6-13
<p>DBL-6-13 is an inhibitor of WDR5, displaying moderate binding affinity with dissociation constants (Kd) of 6.8 μM and 9.1 μM as determined by microscale thermophoresis analysis and fluorescence polarization analysis, respectively.</p>Fórmula:C25H38N4O3Cor e Forma:SolidPeso molecular:442.59SD-2301
CAS:<p>SD-2301 is a PROTAC degrader of STAT3.</p>Fórmula:C64H80N13O15PS2Cor e Forma:SolidPeso molecular:1366.50WDR5 ligand 2
CAS:<p>WDR5ligand 2 is a ligand for WDR5 and can be utilized in the synthesis of PROTAC WDR5degrader 1.</p>Fórmula:C29H31F3N4O4Cor e Forma:SolidPeso molecular:556.576Povorcitinib phosphate
CAS:<p>Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.</p>Fórmula:C23H25F5N7O5PPureza:99.57%Cor e Forma:SolidPeso molecular:605.45STAT3-IN-41
<p>STAT3-IN-41 (Compound 16) is a prodrug of compound 1. It gradually releases compound 1, which inhibits the STAT3 signaling pathway. STAT3-IN-41 exhibits antitumor activity against lung cancer, hepatocellular carcinoma, and pancreatic cancer.</p>Fórmula:C22H30F3NO7Cor e Forma:SolidPeso molecular:477.471Tyrosine Kinase Inhibitor Library
<p>A unique collection of 1016 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related</p>Cor e Forma:Odour SolidPROTAC STAT3 degrader-2
CAS:<p>PROTAC STAT3 degrader-2 selectively breaks down STAT3 (DC50: 3.54μM, Molm-16) with cancer research potential.</p>Fórmula:C59H60F2N9O13PCor e Forma:SolidPeso molecular:1172.13Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidAtinvicitinib
CAS:<p>Atinvicitinib, a selective JAK1 inhibitor, blocks cytokine signaling, modulating itch, allergy, and inflammatory responses, immune and therapeutic studies.</p>Fórmula:C16H17FN6O3Pureza:99.36%Cor e Forma:SolidPeso molecular:360.35CHZ868
CAS:<p>CHZ868 is a type II JAK inhibitor with potential antitumor activity that reverses the persistence of type I JAK inhibitors and can be used to study leukemia.</p>Fórmula:C22H19F2N5O2Pureza:99.38%Cor e Forma:SolidPeso molecular:423.42SD-436
CAS:<p>SD-436 is a selective and highly efficient STAT3 PROTAC degrader (DC50 = 0.5 μM), with an IC50 of 19 nM for STAT3, significantly higher than for STAT1/4/5/6. SD-436 depletes STAT3 and induces tumour regression in mouse leukaemia and lymphoma xenograft models.</p>Fórmula:C58H62F4N9O14PSPureza:99.34%Cor e Forma:SolidPeso molecular:1248.2DTP3
CAS:<p>DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.</p>Fórmula:C26H35N7O5Cor e Forma:SolidPeso molecular:525.6Pim-1/2 kinase inhibitor 1
CAS:<p>Orally active Pim-1/2 inhibitor blocks kinase phosphorylation; used in prostate cancer research.</p>Fórmula:C11H9NO3SPureza:99.78%Cor e Forma:SolidPeso molecular:235.26Itacitinib adipate
CAS:<p>Itacitinib adipate: oral JAK1 inhibitor, tested in phase II myelofibrosis trial.</p>Fórmula:C32H33F4N9O5Cor e Forma:SolidPeso molecular:699.66Ilunocitinib
CAS:<p>Ilunocitinib is a non-selective and orally active Janus kinase (JAK) inhibitor for pruritus and atopic dermatitis caused by atopic dermatitis in dogs.</p>Fórmula:C17H17N7O2SPureza:99.88%Cor e Forma:SolidPeso molecular:383.43AK-1690
CAS:<p>AK-1690 is a potent and selective STAT6 PROTAC degrader that induces degradation of STAT6 proteins in cells and depletes STAT6 proteins in mouse tissues.</p>Fórmula:C51H56F2N5O11PSPureza:99.95%Cor e Forma:SolidPeso molecular:1016.055,15-DPP
CAS:<p>5,15-Diphenylporphyrin (5,15-DPP) is a selective STAT3-SH2 antagonist with IC 50s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively [1].</p>Fórmula:C32H22N4Cor e Forma:SolidPeso molecular:462.54Ifidancitinib
CAS:<p>Ifidancitinib (ATI-50002) is a JAK kinase 1/3 inhibitor used to study autoimmune diseases.</p>Fórmula:C20H18FN5O3Pureza:98.05%Cor e Forma:SolidPeso molecular:395.39FLLL32
CAS:<p>FLLL32 is an effective JAK2/STAT3 inhibitor (IC50 of <5 μM).</p>Fórmula:C28H32O6Pureza:97% - 97.90%Cor e Forma:SolidPeso molecular:464.55Filgotinib
CAS:<p>Filgotinib (GLPG0634) is a selective JAK1 inhibitor. The IC50 values against JAK1, JAK2, JAK3, and TYK2 are 10 nM, 28 nM, 810 nM, and 116 nM, respectively.</p>Fórmula:C21H23N5O3SPureza:98.03% - ≥95%Cor e Forma:SolidPeso molecular:425.5RGB-286638 free base
CAS:<p>RGB-286638 free base inhibits CDKs (1-5 nM), weaker on CDK7/6.</p>Fórmula:C29H35N7O4Pureza:98% - 99.91%Cor e Forma:SolidPeso molecular:545.63JAK3-IN-6
CAS:<p>JAK3-IN-6 is irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM</p>Fórmula:C19H18N4O3Pureza:99.94% - 99.94%Cor e Forma:SolidPeso molecular:350.37Ritlecitinib
CAS:<p>Ritlecitinib (PF-06651600) is an orally available, selective JAK3 inhibitor and does not affect the activity of JAK1/2.Cost-effective and quality-assured.</p>Fórmula:C15H19N5OPureza:98.82% - 99.92%Cor e Forma:SolidPeso molecular:285.34SHR0302
CAS:<p>SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,</p>Fórmula:C18H22N8O2SPureza:99.11%Cor e Forma:SolidPeso molecular:414.48AG490
CAS:<p>AG490 inhibits EGFR (0.1 μM IC50), 135x > selective than ErbB2, blocks JAK2, spares Lyn, Lck, Syk, Btk, Src.</p>Fórmula:C17H14N2O3Pureza:98.6% - 99.39%Cor e Forma:Yellow SolidPeso molecular:294.3RO8191
CAS:<p>RO8191 (CDM-3008) (CDM-3008) is an agonist of interferon (IFN) receptor.</p>Fórmula:C14H5F6N5OPureza:98% - 98.85%Cor e Forma:SolidPeso molecular:373.21SMI-16a
CAS:<p>SMI-16a (PIM1/2 Kinase Inhibitor VI) , a cell-permeable thiazolidinedione compound, acts as an effective, ATP-competitive inhibitor against Pim-1/2 kinases (</p>Fórmula:C13H13NO3SPureza:99.99%Cor e Forma:SolidPeso molecular:263.31SAR-20347
CAS:<p>SAR-20347 is an inhibitor of TYK2, JAK1/2/3 (IC50: 0.6/23/26/41 nM).</p>Fórmula:C21H18ClFN4O4Pureza:98.99% - 99.77%Cor e Forma:SolidPeso molecular:444.84XL019
CAS:<p>XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, 100 fold selectivity over JAK1.</p>Fórmula:C25H28N6O2Pureza:99.19%Cor e Forma:SolidPeso molecular:444.53Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Fórmula:C23H25ClFN7OPureza:99.33% - 99.86%Cor e Forma:SolidPeso molecular:469.94Momelotinib HCl
CAS:<p>Momelotinib HCl is a JAK1/2 inhibitor, reducing anemia in myelofibrosis (MF) patients.</p>Fórmula:C23H24Cl2N6O2Cor e Forma:SolidPeso molecular:487.38Atractylenolide I
CAS:<p>Atractylenolide-I reduces inflammation, improves sepsis, liver, and kidney function, and enhances EOC cell sensitivity to paclitaxel.</p>Fórmula:C15H18O2Pureza:97.55% - 99.92%Cor e Forma:SolidPeso molecular:230.3TCS-PIM-1-4a
CAS:<p>SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).</p>Fórmula:C11H6F3NO2SPureza:99.89%Cor e Forma:SolidPeso molecular:273.23Peficitinib
CAS:<p>Peficitinib (ASP015K) (ASP015K, JNJ-54781532) is an orally bioavailable JAK inhibitor. Phase 3.</p>Fórmula:C18H22N4O2Pureza:98.67% - 99.4%Cor e Forma:SolidPeso molecular:326.39Tofacitinib Citrate
CAS:<p>Tofacitinib Citrate (CP-690550 citrate) is a a potent, cell-permeable inhibitor of JAK1/2/3 (IC50s: 1/20/112 nM).</p>Fórmula:C22H28N6O8Pureza:99.19% - 99.75%Cor e Forma:SolidPeso molecular:504.49Gusacitinib HCl
CAS:<p>Gusacitinib (ASN-002/EN-3351), a potent SYK/JAK inhibitor, has strong antitumor activity in various cancers.</p>Fórmula:C24H29ClN8O2Cor e Forma:SolidPeso molecular:497Ruxolitinib (S enantiomer)
CAS:<p>Ruxolitinib S enantiomer (INCB18424) is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor.</p>Fórmula:C17H18N6Pureza:99.37% - 99.79%Cor e Forma:SolidPeso molecular:306.36
